The stock's fall snapped a four-day winning streak.

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that ...

Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 results ...

This was the stock's fourth consecutive day of gains.

Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Vertex Pharmaceuticals reported decent Q1 earnings ... I/we have a beneficial long position in the shares of VRTX either through stock ownership, options, or other derivatives.

U.S. equities dropped at midday as the markets awaited any news on tariffs and tomorrow's Federal Reserve decision.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.